Conference report: Bimekizumab achieved superior skin clearance in BE VIVID and BE READY phase III studies in adults with moderate-to-severe plaque psoriasis

Both studies of this investigational IL-17A and IL-17F inhibitor met their co-primary superiority endpoints of at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) and IGA response of clear or almost clear skin (IGA 0/1) at week 16.

SPS commentary:

In BE VIVID study, PASI 90 rates (all comparisons p<0.001) were 85.0, 49.7 and 4.8% for bimekizumab, ustekinumab and placebo, respectively. IGA 0/1 rates were 84.1, 53.4 and 4.8%, respectively.


In BE READY, PASI 90 rates were 90.8% for bimekizumab vs. 1.2% placebo and; IGA 0/1 rates were 92.6 and 1.2%, respectively. In the second phase of the study, patients who had achieved at least a PASI 90 response at week 16 were re-randomized to receive continuous bimekizumab at two different dosing regimens or to be withdrawn from treatment. Maintenance of response was similar in the two bimekizumab treatment arms, with 86.8% of patients who received continuous bimekizumab 320mg every 4 week maintaining PASI 90 at week 56, compared to 91% switched to 320mg every 8 weeks and 16.2% of patients who were withdrawn.


Biospace Inc.